Gesynta Pharma’s management and board of directors have experience from senior positions in leading pharmaceutical companies, bringing deep knowledge from all drug development phases – from discovery to the commercialization of approved products.Executive Team Board
The company’s major shareholders include the reputable institutional investors Hadean Ventures, Industrifonden and Linc, as well as successful life science industry entrepreneurs.
Vipoglanstat (GS-248) is a non-hormonal, potentially disease-modifying drug candidate that inhibits the inflammation-related enzyme mPGES-1. In phase I and II clinical trials, the drug candidate has demonstrated a favorable safety profile and beneficial pharmacological properties. Based on these results and robust data from a preclinical proof-of-concept study in an advanced disease model of endometriosis, vipoglanstat is expected to enter a phase II clinical trial in patients with endometriosis in 2023.Read more
Gesynta Pharma’s pipeline presents a broad range of opportunities based on unique anti-inflammatory and pain-relieving properties. The first compound in this next-generation series, GS-073, is ready to enter clinical phase I.Read more
Gesynta Pharma bases its R&D on groundbreaking research from the Karolinska Institutet.
Our executive team and board of directors hold vast experience in drug development, commercialization and company scale-up.
Endometriosis is a chronic, inflammatory, estrogen-dependent disease affecting millions of women worldwide.
Our lead drug candidate vipoglanstat is in phase II, while GS-073 is about to enter phase I.